These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 21544985)
1. Intraocular Hemorrhage due to use of Sildenafil in a Patient with Diabetes. Ilhan C; Uzel MM; Citirik M Med Hypothesis Discov Innov Ophthalmol; 2018; 7(3):122-125. PubMed ID: 30386801 [TBL] [Abstract][Full Text] [Related]
2. Systems Pharmacology and Rational Polypharmacy: Nitric Oxide-Cyclic GMP Signaling Pathway as an Illustrative Example and Derivation of the General Case. Garmaroudi FS; Handy DE; Liu YY; Loscalzo J PLoS Comput Biol; 2016 Mar; 12(3):e1004822. PubMed ID: 26985825 [TBL] [Abstract][Full Text] [Related]
4. [Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction]. Liu Y Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1147-51. PubMed ID: 24432631 [TBL] [Abstract][Full Text] [Related]
5. [Cardiovascular complications of phosphodiesterase-5 inhibitors]. Dworzański W; Jaskólska A; Szumiło M; Switalska A; Burdan F Pol Merkur Lekarski; 2011 Feb; 30(176):139-42. PubMed ID: 21544985 [TBL] [Abstract][Full Text] [Related]
7. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. Azzouni F; Abu samra K J Sex Med; 2011 Oct; 8(10):2894-903. PubMed ID: 21771280 [TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639 [TBL] [Abstract][Full Text] [Related]
9. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999 [TBL] [Abstract][Full Text] [Related]